Testing the addition of immunotherapy in patients with endometrial cancer
The purpose of the study is to test whether the addition of an immunotherapy drug, called tislelizumab, to the standard of care treatment of high-risk endometrial cancer reduces the risk of the disease coming back, and to determine if the new course of therapy is well-tolerated by participants.
What you need to know
Who can take part?
Any patients who have been diagnosed with high-risk endometrial cancer who have received surgery for the condition, and also require radiation and then chemotherapy. This trial can only enrol patients who have surgery in the previous 8 weeks.
What is involved for you?
Patients have standard treatment for their disease, and 2/3 of patients in the trial also receive an additional immunotherapy medication (tislelizumab). Standard of care chemotherapy involves attending the clinic every 3 weeks for chemotherapy for 4 cycles. For patients who are receiving the additional immunotherapy medication (tislelizumab), you will need to continue to attend the clinic for an additional 8 cycles. While in the clinic you will have a physical assessment, blood collection and complete a quality of life survey.
